A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer

Abstract Background Antiangiogenic treatment and immunochemotherapy effectively treat patients with advanced esophageal cancer. However, there remains a dearth of studies concerning neoadjuvant therapy for resectable esophageal cancer. Methods The study focused on patients with T2–4NxM0 resectable e...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Hongtao Duan, Zhaoyang Wang, Lili Cao, Yifang Zhu, Liping Tong, Xiaolong Yan
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2024-07-01
Цуврал:	Thoracic Cancer
Нөхцлүүд:	antiangiogenic chemotherapy neoadjuvant treatment resectable esophageal cancer sintilimab
Онлайн хандалт:	https://doi.org/10.1111/1759-7714.15312
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!